Rui Chen

Discovery of quinoline-based derivatives as c-Met inhibitors for the treatment of non-small cell lung cancer.

The clinical utility of type II mesenchymal-epithelial transition factor (c-Met) inhibitors remains constrained by narrow therapeutic windows and dose-limiting toxicities, underscoring an urgent need for structurally differentiated candidates with improved developability. Herein, we report the design, synthesis, and bi...